ESMO 2022 is wrapped and two studies in particular have caught our eyes:
NICHE-2: neoadjuvant Nivo/Ipi in MMR-d colon cancer
CODEBREAK: sotorasib vs. docetaxel
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
